Novo Nordisk is buying a subsidiary of Prothena that is developing PRX004, which is in Phase 2 trials. The drug is designed to reduce amyloid deposition in amyloidosis. Prothena will receive $100 million and will be entitled to payments for the development and sales of PRX004 up to $1.1 billion.